S-8

As filed with the U.S. Securities and Exchange Commission on March 5, 2026

Registration No. 333-   

 

 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

Climb Bio, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   83-2273741

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

20 William Street, Suite 145

Wellesley Hills, Massachusetts 02481

(866) 857-2596

(Address of principal executive offices) (Zip code)

Climb Bio, Inc. 2021 Equity Incentive Plan

Climb Bio, Inc. 2021 Employee Stock Purchase Plan

Climb Bio, Inc. 2025 Inducement Plan, as amended

(Full title of the plan)

Aoife Brennan, M.B., Ch.B.

President and Chief Executive Officer

Climb Bio, Inc.

20 William Street, Suite 145

Wellesley Hills, Massachusetts 02481

(866) 857-2596

(Name and address of agent for service) (Telephone number, including area code, of agent for service)

 

 

Copy to:

Christopher D. Barnstable-Brown

Scott N. Lunin

Wilmer Cutler Pickering Hale and Dorr LLP

7 World Trade Center

250 Greenwich Street

New York, New York 10007

(212) 230-8800

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 
 


EXPLANATORY NOTE

This Registration Statement on Form S-8, relating to an aggregate of (a) 2,388,316 shares of common stock, par value $0.0001 per share (“Common Stock”), issuable under the 2021 Equity Incentive Plan (the “2021 Plan”) of Climb Bio, Inc. (the “Registrant”), (b) 477,663 shares of Common Stock issuable under the 2021 Employee Stock Purchase Plan (the “ESPP”) of the Registrant and (c) 750,000 shares of Common Stock issuable under the 2025 Inducement Plan, as amended (the “2025 Inducement Plan”), of the Registrant, is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective. Accordingly, this Registration Statement incorporates by reference the contents of the Registration Statement on Form S-8, File No. 333-286303, filed by the Registrant with the Securities and Exchange Commission on April 1, 2025 relating to the 2021 Plan, the ESPP and the 2025 Inducement Plan, except to the extent amended or superseded by the contents hereof.

Item 8. Exhibits.

The following exhibits are incorporated herein by reference:

 

         Incorporated by Reference
Exhibit
Number
  Description   
Form
     File
Number
     Exhibit      Filing Date
 4.1   Amended and Restated Certificate of Incorporation, as amended, of the Registrant.      10-Q        001-40708        3.1     

November

12, 2024

 4.2   Amended and Restated Bylaws of the Registrant.      8-K        001-40708        3.2     

October

2, 2024

 4.3   Form of common stock certificate of the Registrant.      10-K        001-40708        4.1     

March

25, 2025

 5.1*   Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant.            
23.1*   Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.            
23.2*   Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1).            
24.1*   Power of Attorney (included on the signature page of this registration statement).            
99.1   2021 Equity Incentive Plan.      10-K        001-40708        10.1     

March

25, 2025

99.2   2021 Employee Stock Purchase Plan.      10-K        001-40708        10.4     

March

25, 2025

99.3   2025 Inducement Plan, as amended.      10-Q        001-40708        10.1     

November

6, 2025

107*   Filing Fee Table.            

 

*

Filed herewith


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Wellesley Hills, Commonwealth of Massachusetts, on this 5th day of March, 2026.

 

CLIMB BIO, INC.
By:  

/s/ Aoife Brennan

  Aoife Brennan, M.B., Ch.B.
  President and Chief Executive Officer

POWER OF ATTORNEY AND SIGNATURES

We, the undersigned officers and directors of Climb Bio, Inc., hereby severally constitute and appoint Aoife Brennan, M.B., Ch.B., Cindy J. Driscoll and Chandra Adams, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Climb Bio, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature    Title    Date

/s/ Aoife Brennan

  

President, Chief Executive Officer and Director

  

March 5, 2026

Aoife Brennan, M.B., Ch.B.   

(Principal Executive Officer)

  

/s/ Susan Altschuller

  

Chief Financial Officer

  

March 5, 2026

Susan Altschuller, Ph.D., MBA   

(Principal Financial Officer)

  

/s/ Cindy J. Driscoll

  

Senior Vice President, Finance

  

March 5, 2026

Cindy J. Driscoll, MBA   

(Principal Accounting Officer)

  

/s/ Douglas E. Williams

  

Director

  

March 5, 2026

Douglas E. Williams, Ph.D.   

(Chairman)

  

/s/ Alexander Cumbo

  

Director

  

March 5, 2026

Alexander Cumbo      

/s/ Kimberlee C. Drapkin

  

Director

  

March 5, 2026

Kimberlee C. Drapkin, CPA      

/s/ Judith Dunn

  

Director

  

March 5, 2026

Judith Dunn, Ph.D.      

/s/ Andrew Levin

  

Director

  

March 5, 2026

Andrew Levin, M.D., Ph.D.      

/s/ Stephen Thomas

  

Director

  

March 5, 2026

Stephen Thomas, Ph.D.      
EX-5.1

Exhibit 5.1

 

LOGO

+1 212 230 8800 (t)

+1 212 230 8888 (f)

wilmerhale.com

March 5, 2026

Climb Bio, Inc.

20 William Street, Suite 145

Wellesley Hills, Massachusetts 02481

 

  Re:

2021 Equity Incentive Plan

2021 Employee Stock Purchase Plan

2025 Inducement Plan, as amended

Ladies and Gentlemen:

We have assisted in the preparation of a Registration Statement on Form S-8 (the “Registration Statement”) to be filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), relating to an aggregate of 3,615,979 shares of common stock, $0.0001 par value per share (the “Shares”), of Climb Bio, Inc., a Delaware corporation (the “Company”), issuable under the Company’s 2021 Equity Incentive Plan, 2021 Employee Stock Purchase Plan and 2025 Inducement Plan, as amended (collectively, the “Plans”).

We have examined the Certificate of Incorporation and By-Laws of the Company, each as amended and restated to date, and originals, or copies certified to our satisfaction, of all pertinent records of the meetings of the board of directors and stockholders of the Company, the Registration Statement, the Plans and such other documents relating to the Company as we have deemed material for the purposes of this opinion.

In our examination of the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, photostatic or other copies, the authenticity of the originals of any such documents and the legal competence of all signatories to such documents.

We assume that the appropriate action will be taken, prior to the offer and sale of the Shares in accordance with the Plans, to register and qualify the Shares for sale under all applicable state securities or “blue sky” laws.

We express no opinion herein as to the laws of any state or jurisdiction other than the General Corporation Law of the State of Delaware.

It is understood that this opinion is to be used only in connection with the offer and sale of the Shares while the Registration Statement is in effect.

Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized for issuance and, when the Shares are issued and paid for in accordance with the terms and conditions of the Plans, as applicable, the Shares will be validly issued, fully paid and nonassessable.

 

LOGO


Climb Bio, Inc.

March 5, 2026

Page 2

      LOGO

 

We hereby consent to the filing of this opinion with the Commission in connection with the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act. In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.

 

Very truly yours,
/s/ Wilmer Cutler Pickering Hale and Dorr LLP
WILMER CUTLER PICKERING HALE AND DORR LLP
EX-23.1

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Climb Bio, Inc. of our reported date March 5, 2026 relating to the financial statements, which appear in Climb Bio, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2025.

/s/ PricewaterhouseCoopers LLP

Seattle, Washington

March 5, 2026

EX-FILING FEES
S-8 S-8 EX-FILING FEES 0001768446 Climb Bio, Inc. N/A Fees to be Paid 0001768446 2026-03-02 2026-03-02 0001768446 1 2026-03-02 2026-03-02 iso4217:USD xbrli:pure xbrli:shares

Calculation of Filing Fee Tables

S-8

Climb Bio, Inc.

Table 1: Newly Registered Securities

Security Type

Security Class Title

Fee Calculation Rule

Amount Registered

Proposed Maximum Offering Price Per Unit

Maximum Aggregate Offering Price

Fee Rate

Amount of Registration Fee

1 Equity Common Stock, $0.0001 par value per share Other 3,615,979 $ 6.97 $ 25,203,374.00 0.0001381 $ 3,481.00

Total Offering Amounts:

$ 25,203,374.00

$ 3,481.00

Total Fee Offsets:

$ 0.00

Net Fee Due:

$ 3,481.00

Offering Note

1

(1) In accordance with Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. (2) Consists of (i) 2,388,316 additional shares issuable under the 2021 Equity Incentive Plan and (ii) 477,663 additional shares issuable under the 2021 Employee Stock Purchase Plan and (iii) 750,000 additional shares issuable under the 2025 Inducement Plan, as amended. (3) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act and based upon the average of the high and low prices of the registrant's common stock as reported on the Nasdaq Global Market on March 2, 2026.

Table 2: Fee Offset Claims and Sources ☑Not Applicable
Registrant or Filer Name Form or Filing Type File Number Initial Filing Date Filing Date Fee Offset Claimed Security Type Associated with Fee Offset Claimed Security Title Associated with Fee Offset Claimed Unsold Securities Associated with Fee Offset Claimed Unsold Aggregate Offering Amount Associated with Fee Offset Claimed Fee Paid with Fee Offset Source
Rule 457(p)
Fee Offset Claims N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Fee Offset Sources N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A